La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Ainos a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Ainos..

Ainos (NASDAQ:AIMD) Azioni, Catena delle Opzioni

Ainos

Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.

Ainos Inc

OKLO: -7% &#x7C; <a href="https://www.benzinga.com//node/45894052">OKLO stock has given up its prior loss. Oklo shares were trading lower after the company announced a $400 million public offering of common stock.</a>
&nbsp;
HYMC: -22% &#x7C; <a href="https://www.benzinga.com//node/45893479">Hycroft Mining Holding shares are trading lower after the company announced a $40 million public offering of units.</a>
&nbsp;
NEHC: 190% &#x7C; <a href="https://www.benzinga.com//node/45900766">New Era Helium's TCDC JV In Talks With Enterprises For AI Infrastructure Expansion In Texas</a>

Movers

Trading Ideas

Hycroft Mining Holding Corporation - Class A Common Stock

HYMC

NEHC

OKLO

Market-Moving News for June 12th

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the R<a href="https://www.benzinga.com/topic/rsi">SI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Karat Packaging Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>)</h3>
<ul class="wp-block-list">
<li>On June 11, Karat Packaging announced it priced a secondary offering of 1.5 million shares at $27 per share. The company's stock fell around 14% over the past five days and has a 52-week low of $23.00.</li>
<li>RSI Value: 21</li>
<li>KRT Price Action: Shares of Karat Packaging fell 14.7% to close at $26.40 on Wednesday.</li>
<li>Edge Stock Ratings: 57.33 Momentum score with Value at 66.25. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/KRT"><img loading="lazy" decoding="async" width="407" height="178" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071538/image-182.png" alt="" class="wp-image-947461" style="width:300px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071538/image-182.png 407w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071538/image-182-300x131.png 300w" sizes="(max-width: 407px) 100vw, 407px" /></a></figure>
<h3 class="wp-block-heading">Copart Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On May 22, Copart reported a third-quarter revenue miss. The company's stock fell around 19% over the past month and <a href="https://www.benzinga.com/quote/CPRT">has a 52-week low</a> of $48.05.</li>
<li>RSI Value: 25.9</li>
<li>CPRT Price Action: Shares of Copart rose 0.4% to close at $50.50 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0612">cprt stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0612"><img loading="lazy" decoding="async" width="923" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071705/image-183.png" alt="" class="wp-image-947463" style="width:643px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071705/image-183.png 923w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071705/image-183-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071705/image-183-768x691.png 768w" sizes="(max-width: 923px) 100vw, 923px" /></a></figure>
<h3 class="wp-block-heading">Aaon Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAON#NASDAQ">AAON</a>)</h3>
<ul class="wp-block-list">
<li>On May 1, AAON posted upbeat quarterly earnings. Gary Fields, CEO, said, &#8220;We had a strong first quarter. Net sales, gross margin and earnings all experienced quarter-over-quarter improvement. Production of BASX-branded equipment made solid progress as we accelerated backlog conversion, utilizing all four of our major locations, including our new facility in Memphis.&#8221; The company's stock fell around 28% over the past month and has a 52-week<a href="https://www.benzinga.com/quote/AAON"> low of $68.98.</a></li>
<li>RSI Value: 22.6</li>
<li>AAON Ltd Price Action: Shares of AAON fell 3.5% to close at $75.85 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0612">AAON shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0612"><img loading="lazy" decoding="async" width="865" height="806" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071928/image-185.png" alt="" class="wp-image-947468" style="width:613px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071928/image-185.png 865w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071928/image-185-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12071928/image-185-768x716.png 768w" sizes="(max-width: 865px) 100vw, 865px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

News

Pre-Market Outlook

Markets

AAON

CPRT

Top 3 Industrials Stocks That Could Lead To Your Biggest Gains This Month

The euro has lost its position as the second-largest reserve asset globally, with gold taking its place, the European Central Bank (ECB) stated in its 2025 annual review.
The top European financial institution took notice of a surge in central bank purchases and record-breaking prices of <a target="_blank" href="https://www.benzinga.com/topic/gold" rel="noreferrer noopener">the yellow metal</a>. At 20% of reserves, gold is slowly closing the gap on the U.S. dollar, which leads at 46%.
"Adjusted for inflation, real gold prices in 2024 surpassed their previous peak seen during the 1979 oil crisis. Meanwhile, gold reserves held by central banks stand at levels close to those last seen in the Bretton Woods era (36,000 tons), although they now account for a far smaller share of total gold supply," the ECB said in the <a target="_blank" href="https://www.ecb.europa.eu/press/other-publications/ire/focus/html/ecb.irebox202506_01~f93400a4aa.en.html" rel="noreferrer noopener">review</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45893521" rel="noreferrer noopener">US Embassy Evacuations Spark Middle East Risks, And Markets Are Noticing</a>
The bank has stated the persistent rally into 2025, which has (for now) topped at $3,500 per ounce, driven by a mix of investor interest and persistent official sector demand.
The geopolitical shock of Russia's invasion of Ukraine in 2022 triggered a reassessment of reserve strategies among central banks. Concerns over sanctions and the weaponization of reserve currencies drove a shift toward gold, which has long been viewed as a neutral store of value.
This trend was notable among countries geopolitically aligned with or near China and Russia, many of which began increasing their gold holdings in late 2021.
In response, gold demand from the official sector surged to historic highs. Central banks added over <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/02/43512109/gold-extends-records-as-central-banks-rush-to-buy-bullion-miners-eye-sixth-straight-winning-week" rel="noreferrer noopener">1,000 tons of gold</a> in each of the past three years—more than double the pace seen during the 2010s.
In 2024 alone, official sector purchases represented over 20% of global gold demand, effectively doubling the average share of 10% in the previous decade.
According to recent data from the World Gold Council, Türkiye, India, China, and Poland were the <a target="_blank" href="https://www.gold.org/goldhub/gold-focus/2025/05/indias-gold-market-update-gains-hold-despite-demand-pressure" rel="noreferrer noopener">largest gold buyers</a>, collectively adding over 600 tons since the end of 2021. Interestingly, while India recently became the fourth-largest global economy, Poland is its European counterpart and the only regional outperformer in 2024,<a target="_blank" href="https://think.ing.com/snaps/poland-cee-peers-2024/" rel="noreferrer noopener"> ING research</a> showed.
Boosted gold reserves could help these economies to <a target="_blank" href="https://www.benzinga.com/markets/commodities/25/05/45617358/gold-demand-holds-firm-as-dollar-confidence-wavers" rel="noreferrer noopener">safeguard against de-dollarization</a>, and hedge against inflation and political instability.
Despite gold's impressive climb, its dominance is still constrained by supply limitations and competition from other reserve assets. Notably, the global gold supply is expected to grow by just<a target="_blank" href="https://www.benzinga.com/markets/commodities/25/06/45828108/global-gold-supply-to-grow-1-in-2025-report-shows" rel="noreferrer noopener"> 1% in 2025</a>, while the U.S. dollar money supply (M2) has grown by<a target="_blank" href="https://ycharts.com/indicators/us_m2_money_supply_yoy" rel="noreferrer noopener"> 4.44%</a> in the last 12 months.
Price Watch: SPDR Gold Shares ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) is up 25.6% year-to-date.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/commodities/25/06/45891893/is-the-us-secretly-hoarding-gold-expert-says-do-it-first-tell-the-world-after" target="_blank" rel="noreferrer noopener">Is The U.S. Secretly Hoarding Gold? Expert Says ‘Do It First, Tell the World After'</a></li>
</ul>
Photo by FOTOGRIN via Shutterstock

Macro Economic Events

Commodities

Economics

CurrencyShares British Pound Sterling Trust

GLDM

OUNZ

SGOL

PowerShares DB US Dollar Index Bearish Fund

USDU

PowerShares DB US Dollar Index Bullish Fund

Gold Surpasses Euro To Become Second-Largest Reserve Asset, Still Far Behind Dollar, ECB Says

Karooooo Ltd. ("Karooooo") announced the pricing of an underwritten secondary public offering (the "Offering") of 1,500,000 ordinary shares held by Isaias (Zak) Jose Calisto, Karooooo's chief executive officer (the "Selling Shareholder"), at a price to the public of $50.00 per ordinary share (the "public offering price") for total gross proceeds of approximately $75.0 million. The Offering is expected to close on June 13, 2025, subject to customary closing conditions. In addition, the underwriters of the Offering will have a 30-day option to purchase up to an additional 225,000 ordinary shares from the Selling Shareholder at the public offering price. Karooooo's ordinary shares are listed on the Nasdaq Capital Market under the symbol "KARO."
 &nbsp;

KARO

Karooooo Prices Underwritten Secondary Public Offering Of 1.50M Ordinary Shares Held By CEO Isaias Jose Calisto At $50/Shr For Total Gross Proceeds Of ~$75M

Mark Cuban reshared a post supporting Rep. Ro Khanna&#8216;s (D-Calif.) &#8220;Progressive Deficit Reduction Plan,&#8221; which aims to slash the U.S. deficit by $12 trillion over the next decade.
What Happened: Khanna detailed the plan, emphasizing $2.4 trillion in spending cuts as a cornerstone of the initiative. The plan, unveiled on June 10, 2025, seeks to reduce the deficit-to-GDP ratio to 3% by 2034, well below the historical average of 3.8%.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The Republican budget adds $2.4 trillion. This would be 7-8.6 percent of GDP. Our bond markets are fearful that interest rates will go up, and the Fed will have to buy more Treasury bonds, making us all poorer. The historical average of deficit to GDP is under 4 percent. My plan… <a href="https://t.co/CuXUpqSagN">pic.twitter.com/CuXUpqSagN</a>
&mdash; Rep. Ro Khanna (@RepRoKhanna) <a href="https://twitter.com/RepRoKhanna/status/1932453771633688883?ref_src=twsrc%5Etfw">June 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Key components of the spending cuts include modernizing the military and reforming contracting to save $850 billion.
The plans also aim to eliminate Medicare Advantage upcoding and fraud to save $830 billion.
&#8220;Republicans want to slash nearly $1T from Medicare and Medicaid—ripping away healthcare from 16 millions ordinary Americans to pay for tax breaks for billionaires. Instead, we could save $830 billion by ending corporate profiteering. That means cracking down on Medicare Advantage fraud and abuse like upcoding, where private insurers overbill taxpayers and pocket the difference,&#8221; his statement said.
Other key areas of spending cuts include negotiating Medicare drug prices for $200 billion in savings, ending fossil fuel subsidies to save $170 billion, and implementing smarter government procurement for an additional $333 billion.
These measures aim to address inefficiencies and corporate profiteering while investing in critical areas like technology, diplomacy, and healthcare.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/25/06/45886571/gary-blacks-2021-tsla-stock-exit-dodged-a-30-drop-can-valuation-discipline-outsmart-teslas-2025-" target="_blank" rel="noreferrer noopener">Gary Black's 2021 TSLA Stock Exit Dodged A 30% Drop: Can Valuation Discipline Outsmart Tesla's 2025 Robotaxi Hype</a>
Why It Matters: After President Donald Trump was elected, he announced the formation of the Department of Government Efficiency, or DOGE, under the leadership of Elon Musk. It was aimed at reducing wasteful government spending.
According to the <a href="https://doge.gov/savings">official website</a>, its &#8220;estimated&#8221; savings stand at $180 billion.
However, evaluations and independent analyses by many firms and publications have revealed inaccuracies in Musk&#8217;s reported figures. Additionally, federal spending under Trump in 2025 has kept increasing.
While this &#8216;Progressive Deficit Reduction Plan&#8217; challenges the Republican plan to reduce spending, its viability will only be put to the test upon execution.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Thursday. The SPY was down 0.39% at $599.01, while the QQQ declined 0.41% to $530.23, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45899298/automotive-and-apparel-companies-absorbed-tariff-costs-amid-better-than-expected-may-cpi-print-but-dont-expect-that-to-continue-says-expert">Automotive And Apparel Companies &#8216;Absorbed Tariff Costs&#8217; Amid Better Than Expected May CPI Print: &#8216;But Don&#8217;t Expect That To Continue,&#8217; Says Expert </a></li>
</ul>
Photo Courtesy: Kathy Hutchins On Shutterstock

Mark Cuban Backs Ro Khanna's $12 Trillion 'Progressive Deficit Reduction Plan,' Targeting Medicare Fraud And Military Spending

Ultrawide and simplified to deliver a more streamlined and immersive experience at the helm

GRMN

Garmin Unveils GPSMAP 15x3 With Ultrawide 15-Inch Touchscreen For Streamlined And Immersive Helm Experience

Strategic Partnership with The Baldwin Group&nbsp;
On June 11, 2025, Hippo entered into an agreement with The Baldwin Group to form a strategic partnership. Under the terms of the agreement:
<ul>
<li>Hippo will distribute its new construction homeowners product through Baldwin's subsidiary, Westwood Insurance Agency's industry-leading homebuilder network. This will allow Hippo to accelerate the growth of its New Homes business by accessing three times as many new construction homebuyers.</li>
<li>Baldwin will purchase Hippo's existing homebuilder distribution network for $100 million.</li>
<li>Hippo's hybrid fronting platform, Spinnaker, will build upon its decade-long support of Baldwin's MSI Renters and MSI Homeowners programs by providing capacity to a broader range of Baldwin's MGA programs.</li>
</ul>

BWIN

HIPO

Baldwin Group's Westwood To Purchase Hippo's Existing Homebuilder Distribution Network For $100M

LFCR

Lifecore Biomedical Receives Early $10M Payout From Filler Sale, Boosting Balance Sheet And Supporting $300M Revenue Capacity Strategy

INVA

Innoviva Says FDA Grants Priority Review For Zoliflodacin New Drug Application For Treatment Of Uncomplicated Gonorrhea And Assigns Target PDUFA Date of December 15

2028 Financial Targets:
The company is also introducing 2028 financial targets of:
<ul>
<li>Gross written premium of greater than $2 billion</li>
<li>Adjusted net income of greater than $125 million</li>
<li>Adjusted return on equity of greater than 18%</li>
</ul>

Guidance

Hippo Expects 2028 Gross Written Premium Greater Than $2B, Adj Net Income Over $125M, And Adj ROE Greater Than 18%

HC Wainwright &amp; Co. analyst Robert Burns maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and raises the price target from $40 to $47.

Price Target

Analyst Ratings

EXEL

HC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $47

AGAE

Allied Gaming & Entertainment Sues Knighted Group In Federal Court Alleging Undisclosed Stock Accumulation And Board Takeover Scheme Ahead Of August 2025 Vote

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.schrodinger.com%2F&amp;esheet=54272890&amp;newsitemid=20250612910362&amp;lan=en-US&amp;anchor=Schr%26ouml%3Bdinger&amp;index=1&amp;md5=349784118744a499fb4ec9c3ab73e370">Schrödinger</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) today announced encouraging initial clinical data from its ongoing Phase 1, open-label, dose-escalation study of SGR-1505 in patients with relapsed/refractory B-cell malignancies. SGR-1505 was observed to be safe, well tolerated, and clinically active, with responses observed in multiple histologies, including in patients with chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM). These data are being presented in a poster presentation at the European Hematology Association Annual Congress.
"We are very encouraged by the initial results from our Phase 1 study in patients with relapsed/refractory B-cell malignancies. The data presented today, coupled with the differentiated preclinical and safety profiles observed in our previously completed study in healthy volunteers, further increases our conviction about the potential for SGR-1505 to be a best-in-class therapy," said Margaret Dugan, M.D., chief medical officer at Schrödinger. "Dose escalation is complete, and we look forward to discussing these results and our proposed recommended Phase 2 dose with the FDA later this year."
"Despite recent advances in the treatment of B-cell malignancies, resistance to currently available therapies eventually results in treatment failure and disease progression for many patients," said Stephen Spurgeon, M.D., Associate Professor of Medicine, Oregon Health and Science University, and an investigator for the clinical study. "We know that MALT1 plays a critical role in key signaling pathways that drive cancer cell survival and proliferation, making it a promising target for a broad range of B-cell malignancies. Although these data are from an early-phase study, they suggest SGR-1505 demonstrates on-target activity resulting in potential clinical benefit. I look forward to seeing additional data as the study progresses, including response data in patients with aggressive histologies."
"The positive data reported today represent a key milestone for Schrödinger and follow the clinical successes of programs advanced by collaboration partners and companies we have co-founded," said Karen Akinsanya, Ph.D., president, head of therapeutics R&amp;D and chief strategy officer, partnerships at Schrödinger. "These data reinforce the power of Schrödinger's platform to enable the rapid design of differentiated molecules and the impact that our computational approach can have on a drug discovery and development program."
Major Takeaways from the Study
<ul>
<li>As of the data cut-off date, May 13, 2025, 49 patients were enrolled and evaluable for safety, including 18 patients with CLL/SLL, nine with diffuse large B-cell lymphoma (DLBCL), six with Waldenström macroglobulinemia (WM), and five with marginal zone lymphoma (MZL).</li>
<li>Patients had a median of four (range two-nine) prior lines of therapy, with the most common being Bruton's tyrosine kinase (BTK) inhibitors (55.1%), BCL-2 inhibitors (18.4%) and BTK+BCL-2 inhibitors (18.4%).</li>
<li>SGR-1505 was well-tolerated with no dose-limiting toxicities or deaths due to treatment-emergent adverse events (TEAEs). Forty three percent of patients (n=21) experienced ≥ 1 treatment-related adverse event (TRAE), with the most common (≥ 10%) being rash (12%) and fatigue (12%). Ten patients (20%) experienced treatment-emergent serious adverse events (SAEs); one was treatment-related. All blood bilirubin increased TEAEs were asymptomatic, reported in patients with UGT1A1 polymorphisms and none were Grade 4.</li>
<li>Inhibition of IL-2 is a pharmacodynamic biomarker for target engagement and an exploratory endpoint in the study. Preliminary data indicated that SGR-1505 inhibits T-cell derived IL-2 upon ex vivo stimulation achieving the PD target of ~90% inhibition in the majority of PD-evaluable participants treated at ≥ 150 mg QD and all Q12H doses at steady state.</li>
<li>Preliminary efficacy data indicated SGR-1505 was clinically active as a monotherapy in a number of relapsed/refractory B-cell malignancies. Of the 49 participants, 45 patients had at least one follow-up disease assessment or disease progression and were evaluable for preliminary efficacy. The overall response rate (ORR) across all dose levels was 22% (n = 10/45). Thirteen of 49 patients had been on treatment for ≥120 days.
<ul>
<li>Among patients with indolent disease, 3/17 CLL/SLL, 5/5 WM, and 1/5 MZL patients responded. The responses of the three CLL responders were independently reviewed and confirmed, and two had a partial response (PR) with lymphocytosis (PR-L). Two of three CLL patients with partial responses were double-exposed to BTK and BCL-2 inhibitors, and all WM patients were exposed to BTK inhibitors.</li>
<li>The study recently began enrolling patients with aggressive lymphomas into the 300 mg QD and 100 mg Q12H cohorts. A PR was reported in one of four ABC-DLBCL patients.</li>
</ul>
</li>
</ul>

SDGR

Schrödinger Reports 22% Response Rate in Early Trial for Drug-Resistant B-Cell Cancers

<ul>
<li>Hippo's Homebuilder Distribution Network Adds 8 New Homebuilders to Westwood's Client Roster; At Closing, Westwood Will Power the Home Insurance Experience for 20 of the Top 25 Homebuilders Representing Over 35% of Total New Single-Family Homes Built in the U.S. Annually &nbsp;</li>
<li>MSI Enters into Program Administrator Agreement and Claims Administration Agreement with Hippo and its Affiliates to Provide Additional Proprietary Capacity to Westwood's Builder Partners &nbsp;</li>
<li>Hippo and its Affiliates, Including Spinnaker, to Provide Fronting Capacity and Additional Reinsurance Support on MSI Programs</li>
</ul>
The Baldwin Group announced today that, Westwood Insurance Agency LLC ("Westwood"), an indirect subsidiary of The Baldwin Group, has entered into an agreement to acquire from Hippo Holdings, Inc. ("Hippo") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) and its affiliates all the outstanding equity interests of the various entities comprising Hippo's homebuilder distribution network. The Partnership, The Baldwin Group's nomenclature for a strategic acquisition, further solidifies Westwood's position as the preeminent insurance agency for the homebuilding industry. Hippo's homebuilder distribution network generated revenues of approximately $29.2million in the most recent trailing 12-month period1 and is expected to deliver approximately $7 million of adjusted EBITDA over the 12 months following the closing of the Partnership, which is currently anticipated to occur on or around July 1, 2025, subject to certain closing conditions. The Partnership is expected to be neutral to Net Leverage (as defined below) and accretive to 2026 pro forma adjusted Diluted EPS.
Separate from the purchase of Hippo's homebuilder distribution network, Millennial Specialty Insurance, LLC ("MSI"), The Baldwin Group's managing general agency (MGA), has entered into a Program Administrator Agreement and a Claims Administration Agreement with an affiliate of Hippo on a new homebuilder program aimed at providing additional proprietary capacity for Westwood's builder partners. Additionally, Hippo and its affiliates, including Spinnaker Insurance Company, have committed to provide capacity and reinsurance support for existing and potential future MSI programs.

Baldwin Group's Westwood Insurance Agrees To Acquire Homebuilder Distribution Network From Hippo Holdings; Terms Undisclosed

Oshkosh Defense LLC, an Oshkosh Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) business, announced today a three-year contract extension for the Family of Medium Tactical Vehicles A2 (FMTV A2). This award allows the U.S. Army to continue ordering the FMTV A2, including three FMTV A2 Low Velocity Air Drop (LVAD) variants, through February 2028.
&nbsp;
&nbsp;
"The FMTV A2 contract extension enables the Army to continue modernizing its fleet with proven medium tactical vehicles in support of the Army Transformation Initiative and Force Design 2030," said Pat Williams, Chief Programs Officer at Oshkosh Defense. "The FMTV A2 LVAD variants fill a critical capability gap for the Airborne community by replacing an aging fleet with an upgraded capability that can be rapidly deployed in contested and austere environments."
The Oshkosh-designed FMTV A2 fleet delivers critical resupply and proven tactical mobility through a modular architecture developed for increased payload, protection, and mobility with the ability to also seamlessly integrate new and evolving capabilities. Purpose-built to enable dispersed and Multi-Domain Operations (MDO), the FMTV A2 is engineered to incorporate next-generation technologies without compromising operational readiness. Its common platform enhances sustainability, streamlines maintenance, and simplifies lifecycle management.
The award provides the opportunity for continued production and fielding of these mission-critical vehicles into 2030, while preserving a mature U.S.-based supply chain which began with the initial FMTV A1P2 contract in 2009.

Government

Regulations

Oshkosh Defense Lands Army Contract Extension to Keep Supplying Tactical Trucks Through 2028

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) with a Buy and maintains $16 price target.

Reiteration

BWAY

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

Helius Medical Technologies, Inc, a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Deborah Backus, PT, Ph.D., FACRM- Vice President of Research and Innovation at Atlanta's Shepard Center presented the positive results from the PoNS Therapeutic Experience Program, or PoNSTEP, study for people with multiple sclerosis (MS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting on May 29 in Pheonix, Arizona.

HSDT

Helius Medical's PoNSTEP Study Results On PoNS Therapy For MS Gait Improvement Presented At 2025 CMSC Meeting By Shepard Center VP Deborah Backus

GURU Organic Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GURU#TSX">GURU</a>) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 44.44 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $6.50 million which missed the analyst consensus estimate of $8.42 million by 22.85 percent. This is a 18.81 percent decrease over sales of $8.00 million the same period last year.

Earnings

TSX:GURU

GURU Organic Energy Q2 EPS $(0.05), Inline, Sales $6.50M Miss $8.42M Estimate

Nurix Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced positive clinical data from the Company's ongoing NX-5948-301 study, a Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed or refractory B-cell malignancies.
The data include findings from the fully enrolled Phase 1a dose escalation study in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and the ongoing Phase 1a/1b cohorts of patients with Waldenström macroglobulinemia (WM). Talha Munir, M.B. Ch.B, Ph.D., consultant hematologist at Leeds Teaching Hospitals NHS Trust, deputy chair of the United Kingdom National Cancer Research Institute CLL Study Group, and Dima El-Sharkawi, M.B., B.S., M.A., Ph.D., MRCP FRCPath, Consultant Haematologist, Royal Marsden NHS Foundation Trust, Sutton, U.K., will present these data at the 30th European Hematology Association Congress (EHA2025), taking place June 12–15, 2025, in Milan, Italy.
"These data demonstrate an impressive safety and efficacy profile for bexobrutideg with improvement in responses in patients over time, including the notable achievement of a complete response in a patient with CLL and a history of two lines of prior therapy who has been on bexobrutideg treatment for over two years," said Dr. Munir. "Patients with relapsed or refractory CLL and WM who have failed treatments with commonly prescribed BTK inhibitors and other agents due to intolerance or acquired resistance have few therapeutic options. Nurix's bexobrutideg has the potential to address this unmet need and provide a life-changing treatment for patients with CLL and WM."
"With longer time on treatment, we are encouraged by the continued favorable safety profile and high ORR with deepening responses in CLL and WM, including those with clinical and genomic high risk features including CNS involvement," said Paula G. O'Connor, M.D., chief medical officer of Nurix. "We have further expanded our Phase 1b cohorts in select CLL populations and remain on track to initiate pivotal studies in 2025."
"Bexobrutideg offers a next-generation approach to BTK targeting with exquisite selectivity, superior preclinical potency, broad coverage of mutations and demonstrated clinical activity in areas of high unmet medical need," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. "We are not only preparing to initiate pivotal studies in the coming months but are also laying the foundation for the commercialization of bexobrutideg as a differentiated treatment option for patients with B-cell malignancies."
Data presented at EHA2025 include efficacy and safety findings for patients with CLL/SLL in the fully enrolled Phase 1a dose escalation study (n=48). This cohort of CLL patients was a heavily pretreated population that had received a median of four prior lines of therapy (range = 2–12) including prior covalent BTK inhibitors (97.9%), prior BCL2 inhibitors (83.3%), and prior non-covalent BTK inhibitors (27.1%). At baseline, many patients had mutations associated with BTK inhibitor resistance, including mutations in BTK (38.3%) and PLC2G (14.9%). Poor prognostic features were common, including TP53 mutations (44.7%), and five patients (10.4%) had central nervous system (CNS) involvement.
Patients were treated with bexobrutideg at doses ranging from 50 mg to 600 mg once daily by oral administration in the Phase 1a dose escalation study. As of the March 12, 2025 data cut, the median follow up was 9.0 months with most patients still on treatment. Bexobrutideg was well tolerated across all doses evaluated with the most common treatment emergent adverse events of purpura/contusion (45.8%), neutropenia (29.2%) and thrombocytopenia (22.9%), primarily low grade. No new onset atrial fibrillation was observed. Among the efficacy evaluable patients with CLL (n = 47), bexobrutideg treatment resulted in a robust objective response rate (ORR) of 80.9% across all doses tested with a median time to first response of 1.9 months. Many patients experienced deepening of their response with longer time, with multiple conversions from stable disease to partial responses and one patient, who has been on treatment for over two years, experienced a complete response. The median duration of response has not been reached, with 18 patients on treatment for more than a year. Responses were observed across all populations regardless of prior treatment, baseline mutations, or CNS involvement.
The data presented at EHA included patients with WM (n=22) treated with bexobrutideg at doses ranging from 50 mg to 600 mg once daily by oral administration from both the Phase 1a dose escalation and Phase 1b cohort expansion. Among the 22 WM patients, the median age was 72.5 years (range 58-86 years) and the median number of prior lines of therapy was 3 (range 2-5). All 22 patients previously had been treated with a covalent BTK inhibitor (100%), 21 had received prior chemotherapy/chemo-immunotherapy (95.5%), four had received prior non-covalent BTK inhibitor (18.2%), and one patient (4.5%) had received prior treatment with a BCL2 inhibitor. Baseline mutation status in MYD88 and CXCR4 was captured from patient records. 15 patients (68.2%) had mutations in MYD88, and five patients (22.7%) had mutations in CXCR4. Bexobrutideg was well tolerated in patients with WM with a profile that was consistent with the overall study population and previous disclosures. Adverse events (AEs) were predominantly low grade; with the most common being petechiae (27.3%), diarrhea (22.7%), purpura/contusion (18.2%), neutropenia (18.2%), and thrombocytopenia (18.2%). There were no dose limiting toxicities observed and no grade 5 AEs. Two treatment emergent AEs led to drug discontinuation. No new onset atrial fibrillation was observed.​ As of the March 12, 2025 data cut, 19 patients were evaluable for responses. Objective response was observed in 16 patients (84.2%), including two patients (10.5%) with very good partial response (VGPR), 11 patients (57.9%) with partial response (PR), and three patients (15.8%) with minor response (MR). Three patients (15.9%) had a best response of stable disease (SD). Responses were observed in patients regardless of their baseline mutations in MYD88 and CXCR4. Steady reductions in IgM levels were observed starting from the first assessment at four weeks, which continued to deepen, and three patients achieved IgM reductions of greater than 90%.

NRIX

Nurix Reports 81% Response Rate in CLL Drug Trial, With Complete Remission in Long-Term Patient

New Era Helium, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEHC#NASDAQ">NEHC</a>) ("NEHC" or the "Company"), a next-gen exploration and production platform in the Permian Basin, today announced that Texas Critical Data Centers, LLC ("TCDC") its joint venture with Sharon AI, Inc., is in active discussions with certain large enterprise customers to anchor its planned AI infrastructure buildout in Ector County, Texas. While no formal agreement has been signed, the Company is actively working to align TCDC's Permian Basin AI Infrastructure efforts with the needs of a large-scale, high-performance computing (HPC) development.
 &nbsp;

Comments

Ainos

Ainos (AIMD) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO